These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 1582069

  • 1. Kinetic analysis of immune complex solubilization: complement function in relation to disease activity in SLE.
    Sturfelt G, Nived O, Sjöholm AG.
    Clin Exp Rheumatol; 1992; 10(3):241-7. PubMed ID: 1582069
    [Abstract] [Full Text] [Related]

  • 2. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G, Jonsson H, Sjöholm A, Sturfelt G, Svehag SE.
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [Abstract] [Full Text] [Related]

  • 3. Complement-mediated solubilization of immune complexes in systemic lupus erythematosus.
    Sakurai T, Fujita T, Kono I, Kabashima T, Yamane K, Tamura N, Kashiwagi H.
    Clin Exp Immunol; 1982 Apr; 48(1):37-42. PubMed ID: 6979449
    [Abstract] [Full Text] [Related]

  • 4. Prospective analysis of C1 dissociation and complement activation in patients with systemic lupus erythematosus.
    Jonsson H, Sturfelt G, Mårtensson U, Truedsson L, Sjöholm AG.
    Clin Exp Rheumatol; 1995 Apr; 13(5):573-80. PubMed ID: 8575134
    [Abstract] [Full Text] [Related]

  • 5. Complement-mediated solubilization in patients with systemic lupus erythematosus, nephritis or vasculitis.
    Schifferli JA, Morris SM, Dash A, Peters DK.
    Clin Exp Immunol; 1981 Dec; 46(3):557-64. PubMed ID: 7337980
    [Abstract] [Full Text] [Related]

  • 6. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
    Balestrieri G, Pagani D, Tincani A.
    J Clin Lab Immunol; 1983 Nov; 12(3):147-50. PubMed ID: 6663608
    [Abstract] [Full Text] [Related]

  • 7. The effect of sera of patients with systemic lupus erythematosus on artificial immune complexes.
    Bányai A, Szabó G, Csongor J, Sonkoly I, Szegedi G.
    Acta Med Hung; 1985 Nov; 42(1-2):51-7. PubMed ID: 4034337
    [Abstract] [Full Text] [Related]

  • 8. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A, Spaeth PJ, Ghirelli PA, Orecchioni F, Buetler R, Montroni M, Nydegger UE.
    Diagn Immunol; 1983 Nov; 1(4):315-23. PubMed ID: 6333960
    [Abstract] [Full Text] [Related]

  • 9. Complement components, C1 activation and disease activity in SLE.
    Sturfelt G, Sjöholm AG, Svensson B.
    Int Arch Allergy Appl Immunol; 1983 Nov; 70(1):12-8. PubMed ID: 6293980
    [Abstract] [Full Text] [Related]

  • 10. A simple enzyme immunoassay for measurement of immune complex solubilization utilizing preformed peroxidase-antiperoxidase complexes.
    Johansson I, Sturfelt G, Truedsson L.
    J Immunoassay; 1994 Nov; 15(4):393-409. PubMed ID: 7836544
    [Abstract] [Full Text] [Related]

  • 11. Decreased capacity to solubilize immune complexes in sera from patients with systemic lupus erythematosus.
    Aguado MT, Perrin LH, Miescher PA, Lambert PH.
    Arthritis Rheum; 1981 Oct; 24(10):1225-9. PubMed ID: 7306225
    [Abstract] [Full Text] [Related]

  • 12. Reduced complement-mediated immune complex solubilization in leprosy patients.
    Ramanathan VD, Sharma P, Ramu G, Sengupta U.
    Clin Exp Immunol; 1985 Jun; 60(3):553-8. PubMed ID: 3874729
    [Abstract] [Full Text] [Related]

  • 13. Sequential studies of complement activation in systemic lupus erythematosus.
    Sturfelt G, Johnson U, Sjöholm AG.
    Scand J Rheumatol; 1985 Jun; 14(2):184-96. PubMed ID: 4001891
    [Abstract] [Full Text] [Related]

  • 14. Complement components, complement activation, and acute phase response in systemic lupus erythematosus.
    Sturfelt G, Sjöholm AG.
    Int Arch Allergy Appl Immunol; 1984 Jun; 75(1):75-83. PubMed ID: 6086533
    [Abstract] [Full Text] [Related]

  • 15. Complement-mediated solubilization of immune complexes and their interaction with complement C3 receptors.
    Petersen I, Baatrup G, Jepsen HH, Svehag SE.
    Complement; 1985 Jun; 2(2-3):97-110. PubMed ID: 2935361
    [Abstract] [Full Text] [Related]

  • 16. C1 subcomponent complexes: basic and clinical aspects.
    Laurell AB, Sjöholm AG.
    Behring Inst Mitt; 1993 Dec; (93):292-8. PubMed ID: 8172579
    [Abstract] [Full Text] [Related]

  • 17. Alternative complement pathway in hypocomplementemic/normal C1s-C1 inhibitor complex patients with SLE.
    Levy RA, Qamar T, Lockshin MD.
    Clin Exp Rheumatol; 1990 Dec; 8(1):11-5. PubMed ID: 2347130
    [Abstract] [Full Text] [Related]

  • 18. Hydralazine and isoniazid reduce the formation of soluble immune complexes by complement.
    Schifferli JA.
    Immunol Lett; 1985 Dec; 9(5):297-9. PubMed ID: 3997205
    [Abstract] [Full Text] [Related]

  • 19. Influence of factor D concentrations on fluid phase C3 activation, lysis of rabbit erythrocytes and solubilization of immune complexes.
    Sturfelt G, Sjöholm AG, Truedsson L.
    Immunol Lett; 1989 Feb; 20(3):231-6. PubMed ID: 2714846
    [Abstract] [Full Text] [Related]

  • 20. Relative importance of C4 binding protein in the modulation of the classical pathway C3 convertase in patients with systemic lupus erythematosus.
    Daha MR, Hazevoet HM, Hermans J, van Es LA, Cats A.
    Clin Exp Immunol; 1983 Oct; 54(1):248-52. PubMed ID: 6604610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.